Chabiotech Co.,Ltd. (KOSDAQ: 085660)

Market Cap	860.48B
Revenue (ttm)	1.01T
Net Income (ttm)	-2.60B
Shares Out	56.31M
EPS (ttm)	-74.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	162,569
Open	15,090
Previous Close	15,250
Day's Range	15,030 - 15,520
52-Week Range	13,510 - 21,000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Chabiotech Co.,Ltd.

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm...

• Industry: Ophthalmic Goods
• Founded: 2002
• Employees: 271
• Stock Exchange: KOSDAQ
• Ticker Symbol: 085660

Financial Performance

In 2023, Chabiotech Co.,Ltd.'s revenue was 953.95 billion, an increase of 12.95% compared to the previous year's 844.58 billion. Losses were -8.43 billion, -82.27% less than in 2022.